Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/ACTRN12624000380594
ACTRN12624000380594Not yet recruitingUnknown

Efficacy of transcutaneous spinal cord stimulation combined with locomotor training to improve walking ability in people with chronic spinal cord injury: a multi-centre double-blinded randomised sham-controlled trial (eWALK2.0)

euroscience Research Australia0 sites88 target enrollmentStarted: April 2, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Unknown
Status
Not yet recruiting
Sponsor
Enrollment
88
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomised controlled trial
Primary Purpose
Treatment
Masking
Blinded (masking used)

Eligibility Criteria

Ages
16 Years to o limit (—)
Sex
All

Inclusion Criteria

  • •A person will be eligible to participate if they:
  • •have a SCI sustained a minimum of 12 months prior to consent
  • •have a motor level between C2-T11 on one or both sides
  • •have a spinally evoked muscle reflex in at least one quadriceps muscle in response to transcutaneous spinal stimulation
  • •have a total lower limb International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) motor score of at least 4/50
  • •are willing and able to participate in the training program 3 times a week for 12 weeks, including a follow-up telephone call at 6 months after randomisation
  • •are able to take at least two steps with no harnessed body weight support. The steps may be completed with assistance (physically swinging the leg through by the therapist is not allowed), braces, gait aids or within parallel bars.
  • •are able to give informed consent and aged 16 years or over at the time of consent
  • •are considered by their spinal specialist to be medically stable to undertake the program (including clearance for standing/locomotor training)

Exclusion Criteria

  • •A person will be ineligible to participate if they:
  • •have a history of clinically significant autonomic dysreflexia in response to electrical stimulation
  • •cannot tolerate transcutaneous spinal stimulation at 50% of the intensity required to evoke a reflex in the quadricep muscle
  • •have a history of hypotension in response to prolonged standing
  • •have a progressive neurological disease and any other major neurological lesion additional to the spinal cord injury, e.g., a severe traumatic brain injury or stroke
  • •have a history of multiple long-bone fractures, family history of fragility fracture or any disorders of the bone, such as Paget’s disease
  • •have a progressive syringomyelia (syrinx) on serial MRI. Radiological findings that have been evaluated by a neurosurgeon as non-progressive may still be eligible
  • •have had open surgery within the last 3 months
  • •have severe lower limb spasticity or contracture that will interfere with the training program
  • •have any serious medical condition, cognitive impairment, drug dependency, psychiatric illness or behavioural problem preventing them from adhering to the protocol
  • •have an existing pressure ulcer Stage 3 or 4 according to the National Pressure Ulcer Advisory Panel classification
  • •have a previous pressure ulcer treated with a myocutaneous flap using a graft from a locomotor muscle such as the gluteal or hamstring
  • •have any contraindications to electrical spine stimulation such as cardiac pacemaker, lower limb fracture, baclofen pump, pregnancy, or implanted electronic devices
  • •have an upper limb injury preventing prolonged weight bearing through their arms
  • •have had stem cell or olfactory ensheathing cell therapy within the last 5 years
  • •are actively participating, or are in the follow-up period, of any other clinical trials

Investigators

Sponsor
euroscience Research Australia

Similar Trials

Active, not recruiting
Unknown
Exercise responses with transcutaneous spinal cord stimulation (using electrodes placed on the skin surface) following spinal cord injuryChronic (>1 year) motor-complete (AIS A-B) spinal cord injury between C5-T6Nervous System Diseases
ISRCTN17856698niversity of Birmingham28
Not yet recruiting
Phase 1
Studying the effect of transcutaneous spinal cord stimulation in patients with neurogenic shock caused by trauma to sub-axial cervical spine.
CTRI/2023/08/057094Priyadharshan KP
Recruiting
Unknown
Transcutaneous Spinal Cord Stimulation (tSCS) in Therapy to Analyze Long-Term Effects on Spasticity and Gait Impairment in Multiple SclerosisSecondary Progressive Multiple Sclerosis (SPMS)Primary Progressive Multiple Sclerosis (PPMS)Gait impairmentSpasticityG35.3G35.2
DRKS00032742Charité Universitätsmedizin Berlin12
Completed
Not Applicable
Transcutaneous spinal cord stimulation (tSCS) for the treatment of spasticity and gait disorders in multiple sclerosisG35G35.2G35.3Multiple sclerosis
DRKS00023357Charité Campus Charité Mitte14
Suspended
Not Applicable
Transcutaneous spinal direct current stimulation in symptomatic management of patients with diabetic polyneuropathyG63.2Diabetic polyneuropathy
DRKS00013525Klinik für Anästhesiologie, Intensiv-, Palliativ- und Schmerzmedizin; Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Bochum50
Efficacy of transcutaneous spinal cord... | Clinical Trial